Ivim Health, a physician-led virtual medical practice operating across all 50 states, has launched a comprehensive women's hormone health program built around HormoneIQ™. This proprietary assessment tool scores symptoms across six domains — vasomotor symptoms, sleep and energy, mood, cognition, sexual wellness, and body composition — to guide individualized treatment plans and track progress over time.
Ivim Health's women's hormone health program also introduces HypoSpray, a transdermal estradiol formulation designed to provide continuity of care for patients affected by the national estrogen patch shortage.
HormoneIQ™ was developed by Dr. Jessica Duncan and Dr. Taylor Kantor based on the clinical recognition that fluctuating hormone levels during perimenopause often appear normal in standard blood tests. According to the brand, this makes a woman's reported experience of her own body the most meaningful clinical data for guiding treatment.
Women's Hormone Health Programs
Ivim Health Builds a Platform Around HormoneIQ™
Trend Themes
-
Symptom-based Diagnostics — Patient-reported symptom scoring is becoming a data layer for personalized care when conventional lab markers fail to capture fluctuating health conditions.
-
Virtual Menopause Care — Telehealth platforms are expanding into midlife women’s health by combining clinical access, longitudinal tracking, and condition-specific treatment pathways.
-
Hormone Delivery Alternatives — Supply disruptions in established therapies are creating space for new transdermal formats that support continuity and convenience in hormone treatment.
Industry Implications
-
Digital Health — Proprietary assessment tools embedded in virtual care models can differentiate platforms through personalized monitoring and scalable specialty services.
-
Women’s Health — Greater recognition of perimenopause and hormone-related symptoms is opening underserved categories for clinically guided, experience-centered care solutions.
-
Pharmaceuticals — Alternative estrogen formulations highlight opportunities for drug delivery innovation tied to access challenges, adherence, and patient preference.